Incyte (INCY) financial statements

Healthcare · Biotechnology · Market cap $21.8B

Incyte reported revenue of $5.1B in fiscal 2025, up 18.6% a year over 9 years.

Net income was $1.3B and the operating margin 29.5%, against 13.1% in 2016.

The diluted share count rose 3% over the period (dilution).

Revenue and free cash flow

Fiscal years, $ billions.

-202462016201720182019202020212022202320242025RevenueFree cash flow
Embed this chart

Free to use in articles and newsletters with the source line. Paste this HTML:

Income statement

Fiscal years, from Incyte's 10-K filings with the SEC.

Fiscal year2016201720182019202020212022202320242025
Revenue$1.1B$1.5B$1.9B$2.2B$2.7B$3.0B$3.4B$3.7B$4.2B$5.1B
Cost of revenue$58M$79M$94M$114M$131M$151M$207M$255M$312M$372M
Gross profit$1.0B$1.5B$1.8B$2.0B$2.5B$2.8B$3.2B$3.4B$3.9B$4.8B
Research and development$582M$1.3B$1.2B$1.2B$2.2B$1.5B$1.6B$1.6B$2.6B$2.1B
Selling, general and admin$303M$366M$434M$469M$517M$740M$1.0B$1.2B$1.2B$1.4B
Operating income$145M-$243M$129M$402M-$264M$586M$579M$621M$61M$1.5B
Interest expense$39M$7M$2M$2M$2M$2M$3M$3M$2M$2M
Pre-tax income$107M-$312M$115M$487M-$232M$570M$529M$834M$317M$1.7B
Income tax$3M$852,000$6M$40M$63M-$378M$188M$237M$284M$378M
Net income$104M-$313M$109M$447M-$296M$949M$341M$598M$33M$1.3B
EPS (diluted)$0.54-$1.53$0.51$2.05-$1.36$4.27$1.52$2.65$0.15$6.41
Diluted shares194M205M216M218M218M222M224M226M211M201M
Gross margin94.7%94.8%95.0%94.7%95.1%94.9%93.9%93.1%92.6%92.8%
Operating margin13.1%-15.8%6.9%18.6%-9.9%19.6%17.1%16.8%1.4%29.5%
Net margin9.4%-20.4%5.8%20.7%-11.1%31.8%10.0%16.2%0.8%25.0%

Balance sheet

Fiscal years, from Incyte's 10-K filings with the SEC.

Fiscal year2016201720182019202020212022202320242025
Cash and short-term investments$809M$1.2B$1.4B$2.1B$1.8B$2.3B$3.2B$3.7B$1.7B$3.1B
Inventory$4M$6M$7M$11M$16M$28M$42M$63M$59M$101M
Total current assets$994M$1.5B$1.8B$2.5B$2.4B$3.1B$4.1B$4.6B$3.2B$5.0B
Property, plant and equipment$168M$260M$320M$378M$560M$724M$739M$752M$763M$731M
Goodwill$156M$156M$156M$156M$156M$156M$156M$156M$156M$133M
Total assets$1.6B$2.3B$2.6B$3.4B$3.6B$4.9B$5.8B$6.8B$5.4B$7.0B
Total current liabilities$274M$375M$425M$513M$631M$854M$1.2B$1.2B$1.6B$1.5B
Total liabilities$1.2B$672M$720M$828M$950M$1.2B$1.5B$1.6B$2.0B$1.8B
Shareholders' equity$419M$1.6B$1.9B$2.6B$2.6B$3.8B$4.4B$5.2B$3.4B$5.2B
Net debt-$652M-$900M-$1.2B-$1.8B-$1.5B-$2.1B-$3.0B-$3.2B-$1.7B-$3.1B

Cash flow

Fiscal years, from Incyte's 10-K filings with the SEC.

Fiscal year2016201720182019202020212022202320242025
Operating cash flow$305M-$93M$336M$711M-$125M$749M$970M$496M$335M$1.4B
Capital spending$120M$111M$73M$78M$187M$181M$78M———
Free cash flow$184M-$204M$263M$633M-$312M$568M$892M———
Stock-based compensation$96M$133M$148M$167M$178M$183M$188M$216M$266M$249M
Share buybacks (net)——————$0$0-$2.0B$0
Free cash flow margin16.7%-13.3%14.0%29.3%-11.7%19.0%26.3%———
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for INCY.
Open INCY in Investingly

Questions

What was Incyte's revenue in 2025?

$5.1B in fiscal 2025, from its 10-K filing.

From Incyte's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.